ScholarIQanswers from OpenAlex
Chonnam National University Hwasun Hospital
InstitutionResearch output, impact & collaborations
Chonnam National University Hwasun Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Chonnam National University Hwasun Hospital?
ScholarIQrecord summary
Chonnam National University Hwasun Hospital is a research organisation in Hwasun, KR. OpenAlex records 5,747 works and 312,221 citations for it. 1,601 researchers list it as their most recent affiliation.
How many works does Chonnam National University Hwasun Hospital have?
ScholarIQindexed works
Chonnam National University Hwasun Hospital has 5,747 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Chonnam National University Hwasun Hospital have?
ScholarIQcitation count
Chonnam National University Hwasun Hospital has 312,221 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Chonnam National University Hwasun Hospital?
ScholarIQresearcher count
Chonnam National University Hwasun Hospital has 1,601 researchers in the ScholarIQ index.
What is the average h-index at Chonnam National University Hwasun Hospital?
ScholarIQavg h-index
Chonnam National University Hwasun Hospital has an average h-index of 45 in OpenAlex.
What is the ROR of Chonnam National University Hwasun Hospital?
ScholarIQror
The ROR for Chonnam National University Hwasun Hospital is on the source record.
What is the OpenAlex record for Chonnam National University Hwasun Hospital?
ScholarIQopenalex
The OpenAlex for Chonnam National University Hwasun Hospital is on the source record.
What is the Wikidata of Chonnam National University Hwasun Hospital?
ScholarIQwikidata
The Wikidata for Chonnam National University Hwasun Hospital is on the source record.
Who are the most-cited researchers behind Chonnam National University Hwasun Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Chonnam National University Hwasun Hospital?
ScholarIQmost cited works
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi‐Long Wu, Ying Cheng, Jianying Zhou, Shun Lü, Yiping Zhang, Jun Zhao, Dong‐Wan Kim, Ross A. Soo, Sang‐We Kim, Hongming Pan, Yuh‐Min Chen, Chih‐Feng Chian, Xiaoqing Liu, Daniel S.W. Tan, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, Keunchil Park, James Chih‐Hsin Yang, Yi‐Long Wu, Xiaoqing Liu, Zhe Liu, Shun Lu, Xi Chen, Hongming Pan, Mengzhao Wang, YU Shi-ying, Helong Zhang, Yiping Zhang, Jian Fang, Wei Li, Jianying Zhou, Jun Zhao, Ying Cheng, Chih-Hsin Yang, Gee‐Chen Chang, Yuh‐Min Chen, Te‐Chun Hsia, Chih‐Feng Chian, Cheng-Ta Yang, Chin‐Chou Wang, Sang‐We Kim, Keunchil Park, Dong‐Wan Kim, Byoung Chul Cho, Ki Hyeong Lee, Young‐Chul Kim, Ho Jung An, In Sook Woo, Y. Choi, Sang Won Shin, Jong Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Ross A. Soo, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles, Martín Emilio Lázaro Quintela, Enriqueta Felip Font, Anne‐Marie C. Dingemans, Lynne A. Bui
How much of the research on Chonnam National University Hwasun Hospital is open access?
ScholarIQopen access share
75%OPEN ACCESS